WuXi PharmaTech (Cayman) Inc.
WuXi PharmaTech (Cayman) Inc., commonly referred to as WuXi AppTec, is a leading global pharmaceutical and biotechnology company headquartered in China. Founded in 2000, the company has established a strong presence in major operational regions, including North America and Europe, providing comprehensive services across the drug development lifecycle. Specialising in contract research, development, and manufacturing, WuXi AppTec offers unique solutions that streamline the process from discovery to commercialisation. Their core services encompass small molecule and biologics development, as well as advanced manufacturing capabilities, which set them apart in the competitive landscape. With a commitment to innovation and quality, WuXi AppTec has achieved significant milestones, positioning itself as a trusted partner for pharmaceutical companies worldwide. Their dedication to enhancing drug development efficiency has earned them a notable reputation in the industry.
DitchCarbon Score
How does WuXi PharmaTech (Cayman) Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Research Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
WuXi PharmaTech (Cayman) Inc.'s score of 20 is lower than 91% of the industry. This can give you a sense of how well the company is doing compared to its peers.
WuXi PharmaTech (Cayman) Inc.'s reported carbon emissions
In 2019, WuXi PharmaTech (Cayman) Inc. reported total carbon emissions of approximately 78,923,450 kg CO2e, with Scope 1 emissions at about 10,584,380 kg CO2e and Scope 2 emissions at around 68,339,070 kg CO2e. In 2018, the company’s total emissions were about 54,251,660 kg CO2e, comprising approximately 4,182,000 kg CO2e from Scope 1 and about 50,069,660 kg CO2e from Scope 2. Notably, there were no reported Scope 3 emissions for both years. Despite the significant emissions figures, WuXi PharmaTech has not disclosed any specific reduction targets or initiatives aimed at decreasing their carbon footprint. The absence of climate pledges or commitments suggests that the company may still be in the early stages of developing a comprehensive climate strategy. As the pharmaceutical industry increasingly prioritises sustainability, WuXi PharmaTech's future commitments will be crucial in aligning with global climate goals.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2018 | 2019 | |
|---|---|---|
| Scope 1 | 4,182,000 | 00,000,000 |
| Scope 2 | 50,069,660 | 00,000,000 |
| Scope 3 | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
WuXi PharmaTech (Cayman) Inc. is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
